Beryl Drugs Ltd.
Snapshot View

10.40 0.00

27 July 2021, 10:48:00 A.M.
Volume: 1,362

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website
Financial Indicators
Market Cap 5.27 Cr.
Earnings per share (EPS) 0.48 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 21.89 Trailing Twelve Months Ending 2021-03
Industry PE 35.25 Trailing Twelve Months Ending 2021-03
Book Value / Share 15.59 Trailing Twelve Months Ending 2021-03
Price to Book Value 0.67 Calculated using Price: 10.40
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 0.51 Cr. 5,071,700 Shares
FaceValue 10
Company Profile

Beryl Drugs incorporated in 1993 is into manufacturing and marketing of branded, generic pharmaceutical formulations. The company is one of leading manufacturer of I.V.fluids and small volume injectables.

Beryl has emerged into a global network of pharmaceutical manufacturing, research and development, contract manufacturing services and veterinary products. 

The manufacturing facilities of the company are in compliance with WHO GMP specifications.

Company owns brands like BERI-CEF injection, F-Neuron, Amplicillin INJ, P-Mol, Biprox, B-Flox and many more.

The shares of Beryl Drugs are listed on M.P. Stock Exchange, Bombay Stock Exchange and Ahmedabad Stock Exchange.

Products manufactured by the company:

  • Small volume injectables in liquid form
  • Small volume injectables in dry powder form
  • Variety of eye and ear drops
  • I.V.Fluids in polypack and glass bottles
  • Variety of vetrinary medicines

Award/recognition

The company has received ISO 9001:2000 certification for its quality management.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
1 Week
+0.10%
1 Month
+25.60%
3 Month
+78.69%
6 Month
+22.93%
1 Year
+23.81%
2 Year
+71.33%
5 Year
-69.32%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 1.56 6.58 4.26 1.31 2.54 1.74 14.80 8.35 0.63
Return on Capital Employed (%) 4.22 11.09 8.35 4.92 5.55 4.48 16.88 9.96 4.05
Return on Assets (%) 1.08 4.54 2.90 0.83 1.62 1.11 9.08 4.67 0.31

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 6 6 6 7 7 7 7 8 8
Non Curr. Liab. 0 0 0 0 0 0 1 3
Curr. Liab. 3 3 3 4 3 4 4 6 7
Minority Int.
Equity & Liab. 8 9 10 11 10 11 11 14 17
Non Curr. Assets 4 5 5 4 4 4 4 9 9
Curr. Assets 4 4 5 6 6 7 7 5 8
Misc. Exp. not W/O
Total Assets 8 9 10 11 10 11 11 14 17

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 9 15 15 13 13 11 15 13 13
Other Income 0 0 0 0 0 0 1 0 0
Total Income 9 15 15 14 13 11 16 13 13
Total Expenditure -9 -14 -14 -13 -13 -11 -14 -12 -12
PBIDT 1 1 1 1 1 1 2 1 1
Interest 0 0 0 0 0 0 0 0 0
Depreciation 0 0 0 -1 0 0 0 0 -1
Taxation 0 0 0 0 0 0 0 0 0
Exceptional Items
PAT 0 0 0 0 0 0 1 1 0

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 1 1 0 1 0 0 0 3 0
Cash Fr. Inv. -1 -1 0 0 0 0 0 -5 -2
Cash Fr. Finan. 0 0 0 0 0 0 0 2 2
Net Change 0 0 0 1 0 0 0 0 0
Cash & Cash Eqvt 0 0 0 1 1 1 0 0 0

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 24.92 24.92 24.92 24.92 24.92 24.92 24.92 24.92 24.92
Public 75.08 75.08 75.08 75.08 75.08 75.08 75.08 75.08 75.08
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Tue, 20 Jul 2021
Announcement under Regulation 30 (LODR)-Demise
Intimation of Demise of Mr. Babulal Sethi Promoter of the Company
Tue, 20 Jul 2021
Shareholding for the Period Ended June 30 2021
Beryl Drugs Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here
Fri, 09 Jul 2021
Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
0000
Name of the Signatory :- ASHISH BARASKAR
Designation :- Chief Financial Officer

Technical Scans View Details

Mon, 26 Jul 2021
Stock Outperforming Benchmark Index in both 1 Week and 3 Month Stock Outperforming Benchmark Index in both 1 Week and 3 Month
Stock Outperforming Sectoral Index in both 1 Week and 3 Month Stock Outperforming Sectoral Index in both 1 Week and 3 Month
Strongly Outperforming Benchmark Index Strongly Outperforming Benchmark Index
Decreasing Relative Strength - Benchmark index Decreasing Relative Strength - Benchmark index
Strongly Outperforming Sectoral Index Strongly Outperforming Sectoral Index

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 168,769.22 696.90 -1.0%
Divi's Laboratories Ltd. 130,349.05 4,915.00 -0.1%
Dr. Reddy's Laboratories Ltd. 90,021.63 5,329.45 -1.5%
Cipla Ltd. 76,675.40 938.35 -1.3%
Cadila Healthcare Ltd. 61,992.73 610.25 +0.5%
Apollo Hospitals Enterprise Ltd. 58,965.37 4,086.80 -0.4%
Aurobindo Pharma Ltd. 55,837.02 948.70 -0.4%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 58.12 696.90 -1.0%
Divi's Laboratories Ltd. Consolidated 2021-03 65.69 4,915.00 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 46.13 5,329.45 -1.5%
Cipla Ltd. Consolidated 2021-03 31.88 938.35 -1.3%
Cadila Healthcare Ltd. Consolidated 2021-03 29.06 610.25 +0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 392.16 4,086.80 -0.4%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.47 948.70 -0.4%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.63 696.90 -1.0%
Divi's Laboratories Ltd. Consolidated 2021-03 14.02 4,915.00 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 5.14 5,329.45 -1.5%
Cipla Ltd. Consolidated 2021-03 4.18 938.35 -1.3%
Cadila Healthcare Ltd. Consolidated 2021-03 4.77 610.25 +0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.83 4,086.80 -0.4%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.55 948.70 -0.4%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 696.90 -1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,915.00 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 5,329.45 -1.5%
Cipla Ltd. Consolidated 2020-03 0.18 938.35 -1.3%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 610.25 +0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,086.80 -0.4%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 948.70 -0.4%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 696.90 -1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,915.00 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 5,329.45 -1.5%
Cipla Ltd. Consolidated 2020-03 10.09 938.35 -1.3%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 610.25 +0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,086.80 -0.4%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 948.70 -0.4%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 696.90 -1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,915.00 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 5,329.45 -1.5%
Cipla Ltd. Consolidated 2020-03 12.53 938.35 -1.3%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 610.25 +0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,086.80 -0.4%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 948.70 -0.4%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 696.90 -1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,915.00 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 5,329.45 -1.5%
Cipla Ltd. Consolidated 2020-03 17,131.99 938.35 -1.3%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 610.25 +0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,086.80 -0.4%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 948.70 -0.4%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 696.90 -1.0%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,915.00 -0.1%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 5,329.45 -1.5%
Cipla Ltd. Consolidated 2020-03 1,546.98 938.35 -1.3%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 610.25 +0.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,086.80 -0.4%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 948.70 -0.4%